NC
JAZZ icon

nVerses Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

nVerses Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,600
Closed -$290K – 433
2024
Q3 		$290K Buy
+2,600
New +$285K 0.13% 248

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

nVerses Capital's JAZZ Position: Q4 2024 in Review

nVerses Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2024, closing a stake of 2,600 shares — an estimated $290K sold.

nVerses Capital first reported a position in JAZZ in Q3 2024 and held it in 1 quarter. The position peaked at $290K in Q3 2024. 508 funds tracked by Wall St. Rank hold JAZZ as of Q4 2024.

  • nVerses Capital reported no remaining Jazz Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • nVerses Capital sold 2,600 Jazz Pharmaceuticals shares in Q4 2024, an estimated $290K.
  • nVerses Capital first reported a position in Jazz Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • nVerses Capital's Jazz Pharmaceuticals position peaked at $290K in Q3 2024.
  • 508 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.